Comparative Pharmacology
Head-to-head clinical analysis: DEXEDRINE versus DYANAVEL XR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXEDRINE versus DYANAVEL XR 5.
DEXEDRINE vs DYANAVEL XR 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant